Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Liquid Collagen Acquisition is a subsidiary of Shaklee Corporation, established in 2025 to manage the acquisition and global commercialization of the Liquid BioCell collagen technology and product portfolio from Modere. Led by CEO Asma Ishaq, the company focuses on science-backed nutritional supplements that utilize a patented, bio-optimized matrix of hydrolyzed collagen type II, hyaluronic acid, and chondroitin sulfate. Its flagship products, including Liquid BioCell Life+, Skin, and Trim, are designed to support joint mobility, skin hydration, and overall structural resilience. The company operates as a specialized division within Shaklee, leveraging over 110 clinical studies to provide "beauty-from-within" and longevity solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Liquid Collagen Acquisition.